The Journal of Antibiotics
Online ISSN : 1881-1469
Print ISSN : 0021-8820
ISSN-L : 0021-8820
LM 427, A NEW SPIROPIPERIDYLRIFAMYCIN: IN VITRO AND IN VIVO STUDIES
COSTANTINO DELLA BRUNAGIOVANNA SCHIOPPACASSIDOMENICO UNGHERIDANIELA JABÈSENZA MORVILLOAURORA SANFILIPPO
Author information
JOURNAL FREE ACCESS

1983 Volume 36 Issue 11 Pages 1502-1506

Details
Abstract

The spiropiperidylrifamycin LM 427 (4-deoxo-3, 4-[2-spiro-N-isobutyl-4-piperidyl]-(1H)-imidazo-(2, 5-dihydro)rifamycin S) displays a broad spectrum of potent antibacterial activity in vitro. In vivo it is particularly effective in the therapy of experimental tubercular infections of mice. Three schedules of treatment were employed and the best results were obtained when intermittent administrations were used (ED50 of LM 427; 7 times lower than rifampicin). LM 427 is well distributed in tissues of mice and rats, with lung concentrations 10-20 times higher than plasma levels.

Content from these authors
© Japan Antibiotics Research Association
Previous article Next article
feedback
Top